NCT01767766已完成1 期
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose acceptable for participants
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Refractory to or relapsed after at least 1 prior treatment regimen;
- •Eastern Cooperative Oncology Group (ECOG) score of 0 to 2;
- •At least 18 years of age.
排除标准
- •Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥ 2 weeks);
- •Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;
- •Known hepatitis B virus, hepatitis C virus or HIV infection;
- •Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically inhibits the PI3K or mTOR pathway;
研究组 & 干预措施
TGR-1202
Experimental
TGR-1202 Daily Oral Dose
干预措施: TGR-1202 (Drug)
结局指标
主要结局
Maximum Tolerated Dose acceptable for participants
时间窗: 28 days (1 cycle of therapy)
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities.
次要结局
- Overall Response Rate(Up to 1 year)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLB-cell Non Hodgkin LymphomaCLLNCT03283137University of Chicago20
招募中
1 期
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid TumoursSolid TumorKRAS Mutation-Related TumorsNCT06237413Suzhou Zelgen Biopharmaceuticals Co.,Ltd110
已完成
1 期
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRelapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)NCT03787498Opna Bio LLC22
终止
1 期
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal CancerColorectal NeoplasmsNCT04194034Transgene15
进行中（未招募）
1 期
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's LymphomaLymphoma, Non-HodgkinRefractory B-Cell NHLRelapsed B-cell NHLNCT06470438Janssen Research & Development, LLC58